Pulmonary Pharmacology and Therapeutics

Pulmonary Pharmacology and Therapeutics





Editor-in-Chief::Mario Cazzola





Go to Journal Website

Personal Print Journal

Subscription Details

Estimated Delivery Time

In Stock

USD 316.00


Subscription Details

ScienceDirect Subscription

  • Access for 5 users
  • Access to 4 years of archives

USD 1,312.80

Print Journal

Subscription Details

Estimated Delivery Time

In Stock

USD 1,312.00
Buying for Institutions
Terms & Conditions

Additional Subscription Help


Aims & Scope

Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews.

Research Areas Include:

All major diseases of the lung
Drug delivery
Pulmonary Toxicology

Before submitting, please note the "Rules of 5" defining immediate rejection criteria of PPT:

1. Out of scope: The paper should report on the use of pharmacological or toxicological studies (positive or negative) that are directly related to Pulmonary Pharmacology & Therapeutics.

Immediate rejection criteria are:
a) Testing of extracts or plant parts that are not characterized
b) Case Reports or n=1 studies

2. Too preliminary: A paper must be based on a thorough and extensive study, using proper controls

Immediate rejection criteria are:
a) In vitro studies with a single dose, or very high concentration b) Single dose studies with very few animals, no dose-response studies c) No proper controls. d) Repetition or confirmation of an earlier work

3. Unethical: The study must have been carried under appropriate ethical approval for the study (either animal or human).

4. Inappropriate experiments or lacking essential detail

Immediate rejection criteria are: a) Wrong species or lacking details on the exact number of animals/subjects used
b) No details of structure if a new drug is used for the first time

5. Lack of novelty: The study must represent a novel approach to the field.

Immediate rejection criteria are:
a) Repetition of well known data
b) No advance of knowledge in the field

Note that only manuscripts written in good English will be considered by the Editors (British usage is preferred).


Abstracting and Indexing

ADONIS, Biological Abstracts, Current Awareness in Biological Sciences, Current Contents, EMBASE, Excerpta Medica, Research Alert, Scopus
Editor-in-Chief: M. Cazzola Unit of Respiratory Clinical Pharmacology, Dept. of Internal Medicine, Università di Roma "Tor Vergata", via Montpellier 1, 00133 Rome, Italy, Editorial Board: I.M. Adcock London, England, UK, M. Adner Stockholm, Sweden, F. Blasi Milan, Italy, G.G. Brusselle Gent, Belgium, J.K. Burgess Sydney, NSW, Australia, L. Calzetta Rome, Italy, B.J. Canning Baltimore, MD, USA, Z. Diamant Heiloo, Netherlands, P. Dicpinigaitis Bronx, NY, USA, A.J. Halayko Winnipeg, MB, Canada, N.A. Hanania Houston, TX, USA, I. Horvath Budapest, Hungary, S.A. Jones London, UK, R. Lever London, UK, M.G. Matera Napoli, Italy, C.J. Molloy New Brunswick, NJ, USA, E. Pizzichini Florianópolis, Brazil, K.F. Rabe Großhansdorf, Germany, K. Racké Bonn, Germany, D. Spina London, UK, A.G. Stewart Parkville, VIC, Australia, J.P.T. Ward London, UK, Honorary Editors: Peter Barnes London, UK, Clive Page London, England, UK
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy

Contact Us

Author Services

Prepare your Article for submission
Translation Services
English Language Editing

Celebrate your publication success
Article Offprints, Journal Issues, Article/Cover Posters, Create Your Own Book

Additional Services
Mobile Apps,Special Content Offerings,and more...